We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Endothelial cell-derived interleukin-6 regulates tumor growth
© Neiva et al.; licensee BioMed Central Ltd. 2014
- Received: 29 October 2013
- Accepted: 12 February 2014
- Published: 17 February 2014
Endothelial cells play a complex role in the pathobiology of cancer. This role is not limited to the making of blood vessels to allow for influx of oxygen and nutrients required for the high metabolic demands of tumor cells. Indeed, it has been recently shown that tumor-associated endothelial cells secrete molecules that enhance tumor cell survival and cancer stem cell self-renewal. The hypothesis underlying this work is that specific disruption of endothelial cell-initiated signaling inhibits tumor growth.
Conditioned medium from primary human dermal microvascular endothelial cells (HDMEC) stably transduced with silencing RNA for IL-6 (or controls) was used to evaluate the role of endothelial-derived IL-6 on the activation of key signaling pathways in tumor cells. In addition, these endothelial cells were co-transplanted with tumor cells into immunodefficient mice to determine the impact of endothelial cell-derived IL-6 on tumor growth and angiogenesis.
We observed that tumor cells adjacent to blood vessels show strong phosphorylation of STAT3, a key mediator of tumor progression. In search for a possible mechanism for the activation of the STAT3 signaling pathway, we observed that silencing interleukin (IL)-6 in tumor-associated endothelial cells inhibited STAT3 phosphorylation in tumor cells. Notably, tumors vascularized with IL-6-silenced endothelial cells showed lower intratumoral microvessel density, lower tumor cell proliferation, and slower growth than tumors vascularized with control endothelial cells.
Collectively, these results demonstrate that IL-6 secreted by endothelial cells enhance tumor growth, and suggest that cancer patients might benefit from targeted approaches that block signaling events initiated by endothelial cells.
- Cervical Cancer
- Signaling pathways
- Molecular targeted therapy
Uterine cervix carcinoma (UCC) includes malignant lesions arising from the tissues of the cervix, and represents the 3rd most common cancer in women worldwide with approximately 529,800 new cases diagnosed every year . The three major histological types of invasive cervical cancer are squamous cell carcinoma (SCC), adenocarcinomas (AC) and adenosquamous carcinoma (ASC). SCC comprise 80% of cases, and adenocarcinomas and ASC comprise approximately 20% [1, 2]. In developed countries, its incidence has showed a marked decline over the past 40 years because of widespread screening with cervical cytology. This decline is mainly attributable to a decrease in the incidence of squamous cell carcinoma [3–10]. On the other hand, there has been a relative increase in the incidence of adenocarcinomas and adenosquamous carcinoma of the cervix over the same period. Notably, the pathobiology of adenocarcinomas remains unclear, particularly the impact of the crosstalk between endothelial cells and tumor cells to cancer growth and progression. Better understanding of signaling events that mediate endothelial cell-tumor cell interactions will lead to the development of improved therapies for uterine cervix adenocarcinomas.
Tumor progression requires the formation of new blood vessels . Therefore, several angiogenesis inhibitors have been developed to target endothelial cells and block tumor growth . Targeting cells that support tumor growth, rather than the cancer cells themselves, is an attractive approach for cancer therapy. The vascular endothelium is directly accessible to drugs injected in the circulation, and is composed of cells that are more stable genetically when compared to cancer cells [13–15]. Notably, studies have suggested that both tumor and non-tumor cells may be involved in reduced responsiveness to therapy by developing acquired resistance . Despite significant advances in therapies targeting angiogenic molecules, the survival benefits of these treatments are relatively modest , the treatments are costly , and have significant side effects [18, 19]. In addition, single-agent therapy that is effective initially may ultimately lead to drug resistance  and tumor recurrence.
The development of molecular targeted therapies may lead to the rational selection of treatment for adenocarcinoma patients based on specific molecular mechanisms whose deregulated activity contributes to the initiation, development, and metastatic spread [21–24]. The deregulation of signaling cascades including the transcription factor signal transducer and activator transcription 3 (STAT3) pathway has been implicated in the pathogenesis of cervical cancer . Notably, the overexpression of activated STAT3 is accompanied by poor prognosis in this sub-group of tumors . It is well known that recombinant interleukin-6 (IL-6) induces STAT3 activation . However, the effect of endothelial cell-secreted IL-6 on tumor cell STAT3 and overall tumor growth is not known. The characterization of the functional impact of the crosstalk between endothelial cells and tumor cells on tumor growth and progression may unveil endothelial cell-secreted molecules as a new conceptual target for cervical cancer therapy.
The prevalent paradigm in tumor biology is that tumor cells secrete factors that drive tumor growth and that endothelial cells simply respond by generating new blood vessels that support the high metabolic demands of tumor cells. Here, we challenged this paradigm and observed that endothelial cell IL-6 levels have a direct impact on tumor cell phenotype and tumor growth in vivo. Our results demonstrate that endothelial cell-secreted IL-6 defines the growth of adenocarcinomas in preclinical models.
Cervical adenocarcinoma cells (HeLa Cells) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). Tumor cells were serum-starved overnight before adding treatment. An immortalized human oral keratinocyte cell line (HOK-16B, gift of No-Hee Park, University of California, Los Angeles) was cultured in serum free medium (OKM; ScienCell, Carlsbad, CA) containing 1% penicillin/streptomycin, and supplemented with 5 μg/ml BSA, 5 μg/ml transferring, 50 μg/ml bovine pituitary extract, 2.5 μg/ml insulin, 1 ng/ml FGF, 500 ng/ml epinephrine, 1 μg/ml hydrocortisone, 30 nM prostaglandin, and 40 μg/ml plant extract (OKGS, BulletKit, ScienCell). Primary human dermal microvascular endothelial cells (HDMEC; Cambrex, Walkersville, MD) were cultured in endothelial growth medium-2 (EGM2-MV; Cambrex). Conditioned medium (CM) from HDMEC or HeLa were prepared in endothelial cell medium (EBM) without supplementation with growth factors or serum from 24-hour cultures.
Stable short hairpin RNA (shRNA) transduction
Lentiviruses expressing a short hairpin RNA (shRNA) construct for silencing IL-6 (Vector Core, University of Michigan) were generated in human embryonic kidney cells (293 T) transfected by the calcium phosphate method, as described . A scrambled oligonucleotide sequence (shRNA-C) was used as control. Supernatants were collected 48 hours after transfection and used to infect HDMEC in 1:1 dilution medium containing 4 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO). Cells were selected in EGM2-MV supplemented with 1 μg/ml puromycin (InvivoGen, San Diego, CA). Downregulation of IL-6 was confirmed by ELISA.
8 × 105 HeLa were plated in 60 mm dishes, starved overnight, and exposed to EBM, or conditioned medium (CM) collected from HDMEC or HeLa for the indicated time points. HDMEC CM and HeLa CM were normalized by total protein concentration. In addition, HOK-16B were exposed to HDMEC CM. Alternatively, tumor cells were exposed to rhIL-6 (BDP, NCI, Frederick, MD) for the indicated time points. Signaling pathways were blocked by pre-incubating tumor cells for 1-2 hours with 20 μM Stattic (STAT3 inhibitor V, Calbiochem, San Diego, CA), 20 μM LY294002 (PI3 kinase inhibitor, Cell Signaling Technology, Danvers, MA), or 20 μM U0126 (MEK1/2 inhibitor, Cell Signaling), as described , and exposed to HDMEC CM or rhIL-6 for the indicated time points. Lysates (30 μg) were electrophoresed in SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Primary antibodies were: mouse anti-human phospho-STAT3, rabbit anti-human STAT3, rabbit anti-human phospho-Akt, rabbit anti-human Akt, rabbit anti-human phospho-ERK1/2, mouse anti-human ERK1/2 (Cell Signaling); and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, Millipore, Billerca, MA). Phosphorylation antibodies detected endogenous levels of STAT3, Akt, and ERK1/2 when phosphorylated at Tyrosine 705, Serine 473, and Threonine 202/Tyrosine 204, respectively. Immunoreactive proteins were visualized by SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, Rockford, IL).
Enzyme-linked immunosorbant assay (ELISA)
Supernatants of endothelial or tumor cell cultures (24 hours) were collected and centrifuged. IL-6 expression was determined using ELISA kits (Quantikine; R & D Systems, Minneapolis, MN) according to the manufacturer’s instructions. Data were normalized by cell number.
SCID mouse model of human tumor angiogenesis
Xenograft human tumors vascularized with human blood vessels were generated under an UCUCA approved protocol, as described [27–29]. Briefly, highly porous poly-L(lactic) acid (Boehringer Ingelheim, Ingelheim, Germany) scaffolds were seeded with 9 × 105 HDMEC and 1 × 105 HeLa in a 1:1 mixture of growth factor reduced Matrigel and EGM2-MV. In addition, scaffolds were seeded with 9 × 105 HDMEC-shRNA-control or HDMEC-shRNA-IL-6 and 1 × 105 HeLa. Severe combined immunodeficient (SCID) mice (5-7-week-old male CB.17.SCID; Charles River, Wilmington, MA) were anesthetized with ketamine and xylazine, and 2 scaffolds were implanted in the subcutaneous space of the dorsal region of each mouse, i.e. one scaffold seeded with HDMEC-shRNA-control + HeLa and one scaffold seeded with HDMEC-shRNA-IL-6 + HeLa. Tumors were measured with a caliper every 2 days, starting at 14 days after implantation. Mice were euthanized after 28 days, implants were retrieved, photographed, measured, weighed, fixed overnight in 10% buffered formalin at 4°C, and embedded in paraffin following standard histological procedures. These studies were performed two independent times to verify the reproducibility of the work under a protocol reviewed and approved by the University of Michigan Committee on Use and Care of Animals (UCUCA). The total “n” of each experimental condition was n = 12 tumors.
Immunohistochemistry of tissue sections
Immunohistochemistry was performed in paraffin-embedded serial sections using phospho-STAT3 (Santa Cruz), STAT3, phospho-Akt, Akt, phospho-ERK, ERK (Cell Signaling), and Ki67 (Biocare Medical, Concord, CA) antibodies, as described .
Tumor microvessel density
Tumor microvessel density was determined following identification of blood vessels by immunohistochemistry with a polyclonal anti-human factor VIII antibody (Lab Vision, Fremont, CA), as previously described [27, 28]. The number of stained microvessels was counted in 10 random fields per implant in a light microscope at 100×. Twelve implants were analyzed per condition.
T-tests or one-way ANOVA followed by appropriate post-hoc tests were performed using SigmaStat 2.0 (SPSS; Chicago, IL). Statistical significance was determined at P < 0.05.
Endothelial cell-secreted factors activate key signaling pathways in tumor cells
To evaluate whether the trends of endothelial cell-induced phosphorylation of STAT3, Akt, and ERK in tumor cells in vitro translate into increased phosphorylation levels in vivo, we used the SCID mouse model of human tumor angiogenesis in which we engineer cervical cell adenocarcinomas vascularized with human functional blood vessels that anastomize with the mouse vasculature [27–29]. We implanted highly porous biodegradable scaffolds containing primary human endothelial cells (HDMEC) together with cervical adenocarcinoma cells (HeLa) in the subcutaneous of SCID mice and analyzed the tissues by immunohistochemistry 28 days after transplantation. We observed that tumor cells adjacent to blood vessels showed phosphorylation of STAT3, Akt, and ERK (Figure 1C). In contrast, the expression of total STAT3, Akt, and ERK was relatively uniform throughout the tissues (data not shown).
Endothelial cell-induced STAT3 phosphorylation is independent of Akt and ERK
Then, we extended the time course experiments to 24 hours, and observed the same relationship between STAT3, Akt, and ERK phosphorylation in tumor cells induced by endothelial cell-secreted factors (Additional file 1: Figure S1). STAT3, Akt, and ERK phosphorylation were stronger at early time points (15 to 30 minutes), and decreased over time. STAT3 phosphorylation decreased at 1 hour and was maintained for up to 24 hours, phosphorylation of Akt decreased at 2 hours and disappeared at 4 to 24 hours, while phosphorylation of ERK decreased significantly at 1 hour and was absent at 3 to 24 hours (Additional file 1: Figure S1A). Inhibition of STAT3 phosphorylation did not affect Akt or ERK phosphorylation levels (Additional file 1: Figure S1B). On the other hand, inhibition of Akt phosphorylation increased activation of ERK (Additional file 1: Figure S1C), and inhibition of ERK phosphorylation increased Akt activation (Additional file 1: Figure S1D). No major effect was observed in STAT3 phosphorylation levels using Akt or ERK inhibitors. Collectively, these studies demonstrated that endothelial cell-induced Akt and ERK phosphorylation in tumor cells induce a mutually compensatory effect, while the STAT3 pathway is activated independently.
IL-6 induces the STAT3 signaling pathway in tumor cells
These results led us to further explore the IL-6/STAT3 signaling in vivo. We used the SCID mouse model of human tumor angiogenesis to generate human adenocarcinomas. We observed that while total STAT3 was present diffusely through the entire tissue (Figure 3B, a), phosphorylated STAT3 showed a tendency to localize adjacent to blood vessels (Figure 3B, b). Interestingly, immunostaining for the cell proliferation marker Ki67 showed the same pattern as phosphorylated STAT3 (Figure 3B, c). These results suggested that phosphorylation of STAT3 in xenograft carcinomas correlates with tumor cell proliferation and the proximity to blood vessels.
Silencing of endothelial cell-IL-6 is sufficient to inhibit tumor growth
A better understanding of the molecular mechanisms underlying the development and progression of the cervical adenocarcinoma may help to identify novel targets for pharmacological intervention in this devastating disease. We have shown that factors secreted by endothelial cells increase tumor cell survival and migration in vitro. Here, we investigated the impact of endothelial cell-initiated signaling events to the pathobiology of cervical adenocarcinomas in vivo.
It has been shown that conditioned medium collected from endothelial cells stimulate phosphorylation of STAT3, Akt, and ERK in head and neck squamous cell carcinomas . However, it is not known whether the ability to activate these pathways was unique to endothelial cells, or if tumor cells themselves could also induce these signaling events. Several studies describe an autocrine effect of tumor cell-secreted factors on cancer progression [31–33]. Here, we demonstrated that tumor cells exposed to endothelial cell conditioned medium showed significantly higher levels of STAT3, Akt, and ERK phosphorylation than tumor cells exposed to conditioned medium collected from tumor cells. Several studies have shown that deregulation of STAT3, Akt, and ERK signaling is implicated in tumorigenesis [34–39], suggesting that aberrant activity of a network of interrelated signaling pathways, rather than a single deregulated route, contributes to carcinogenesis. We observed that while levels of total STAT3, Akt, and ERK were uniformly distributed throughout the xenograft tumors, the expression of phosphorylated STAT3, Akt, and ERK was more clustered around blood vessels. These results provide further evidence that endothelial cell-secreted factors may play a role in the activation of these pathways within the tumor microenvironment.
To our knowledge, the crosstalk between STAT3, Akt, and ERK pathways has not been studied in cervical cancer. Trying to understand the relationship between these endothelial cell-initiated signaling events on tumor cells, we exposed tumor cells to endothelial cell conditioned medium in the presence of chemical inhibitors of STAT3, Akt, and ERK pathways. Our results showed that endothelial cell-induced Akt and ERK signaling have a mutually compensatory effect, while STAT3 pathway appears to be activated independently. These results are in accordance with accumulating evidence that Akt and ERK pathways may cooperate to promote the survival of transformed cells, and are alternatively and/or coordinately expressed in several cancers, raising the possibility that a feedback loop might exist in this network [40–44].
It is well established that activation of the STAT3 signaling pathway promotes tumor growth and expression of pro-angiogenic factors . We observed that blockade of endothelial cell-derived IL-6 inhibited STAT3 phosphorylation in cancer cells  and expression of CXCL8 (IL-8), a potent pro-angiogenic factor that is strongly correlated with tumor microvessel density . Indeed, despite the fact that endothelial cells secrete many cytokines and growth factors, silencing of IL-6 with shRNA (or use of a netutralizing antibody) completely abrogated induced phosphorylation of STAT3 in tumor cells . Notably, expression of IL-6 is higher in endothelial cells than in the tumor cells themselves (data not show). Here, we reported that xenograft tumors engineered with endothelial cells stably transduced with shRNA-IL-6 exhibit lower microvessel density. These results corroborate the hypothesis that IL-6 mediates a pro-angiogenic paracrine loop that plays an important role in tumor growth and angiogenesis. In other words, downregulation of IL-6 secreted by endothelial cells inhibits phosphorylation of STAT3 in tumor cells, which will then secrete less angiogenic factors (e.g. CXCL8) causing a decrease in tumor microvessel density and tumor growth.
Notably, tumor cells expressing phosphorylated STAT3 localized primarily adjacent to blood vessels and correlated with expression of the proliferation marker Ki67. We only analyzed Ki67 positivity adjacent to blood vessels in both groups to eliminate possible differences due to hypoxia. Expression of Ki67 in tumor cells and tumor microvessel density were lower in tumors vascularized with IL-6-silenced endothelial cells. Early studies have shown that Bcl-2 is upregulated in tumor-associated endothelial cells, that upregulation of Bcl-2 in microvascular endothelial cells accelerates tumor growth, and that endothelial cells overexpressing Bcl-2 secrete higher levels of IL-6 than vector control cells [25–28] These findings, along with the results presented here, begin to provide a possible mechanism for the impact of endothelial cell-derived IL-6 on tumor growth.
Targeted disruption of the vascular endothelium has been proposed by Dr. Folkman four decades ago and has shown efficacy in some tumor types [11–13, 47]. However, this approach results in hypoxic, nutrient-deprived tumor microenvironments that can be associated with enhanced motility of tumor cells and development of evasive resistance to therapy . Here, we showed that specific blockade of the endothelial cell-tumor cell crosstalk (e.g. IL-6) is sufficient to inhibit tumor growth. These results suggest that cervical cancer patients might benefit from the therapeutic blockade of key signaling events that regulate the crosstalk between endothelial cells and tumor cells.
The authors thank No-Hee Park (University of California Los Angeles) for the HOK-16B cells used here. We also thank Kitrina Cordell, Valerie Castle, Cun-Yu Wang, and Peter Polverini for their thoughtful input and strong support to this project. This work was funded by grant P50-CA-97248 (University of Michigan Head and Neck SPORE) from the NIH/NCI; and grants R21-DE19279 and R01-DE21139 from the NIH/NIDCR (JEN).
Funded by grant P50-CA-97248 (University of Michigan Head and Neck SPORE) from the NIH/NCI; and grants R21-DE19279 and R01-DE21139 from the NIH/NIDCR (JEN).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.View ArticlePubMedGoogle Scholar
- Committee on Practice B-G: ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstet Gynaecol. 2002, 99: 855-867.View ArticleGoogle Scholar
- Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L: Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer. 1990, 65: 2507-2514. 10.1002/1097-0142(19900601)65:11<2507::AID-CNCR2820651120>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Lai CH, Hsueh S, Hong JH, Chang TC, Tseng CJ, Chou HH, Huang KG, Lin JD: Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. Int J Gynecol Cancer. 1999, 9: 28-36. 10.1046/j.1525-1438.1999.09895.x.View ArticlePubMedGoogle Scholar
- Smith HO, Tiffany MF, Qualls CR, Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States–a 24-year population-based study. Gynecol Oncol. 2000, 78: 97-105. 10.1006/gyno.2000.5826.View ArticlePubMedGoogle Scholar
- Sasieni P, Adams J: Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001, 357: 1490-1493. 10.1016/S0140-6736(00)04646-8.View ArticlePubMedGoogle Scholar
- Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S: Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004, 100: 1035-1044. 10.1002/cncr.20064.View ArticlePubMedGoogle Scholar
- Sherman ME, Wang SS, Carreon J, Devesa SS: Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005, 103: 1258-1264. 10.1002/cncr.20877.View ArticlePubMedGoogle Scholar
- Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidem Biomarkers Prev. 2005, 14: 2191-2199. 10.1158/1055-9965.EPI-05-0231.View ArticleGoogle Scholar
- Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nat Cancer Inst. 2006, 98: 303-315. 10.1093/jnci/djj067.View ArticlePubMedGoogle Scholar
- Folkman J: Tumor angiogenesis: therapeutic implications. New Eng J Med. 1971, 285: 1182-1186. 10.1056/NEJM197111182852108.View ArticlePubMedGoogle Scholar
- Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002, 2: 727-739. 10.1038/nrc905.View ArticlePubMedGoogle Scholar
- Kerbel RS: Tumor angiogenesis. New Eng J Med. 2008, 358: 2039-2049. 10.1056/NEJMra0706596.View ArticlePubMedPubMed CentralGoogle Scholar
- St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science. 2000, 289: 1197-1202. 10.1126/science.289.5482.1197.View ArticlePubMedGoogle Scholar
- Kolonin M, Pasqualini R, Arap W: Molecular addresses in blood vessels as targets for therapy. Curr Opinion Chem Biol. 2001, 5: 308-313. 10.1016/S1367-5931(00)00207-6.View ArticleGoogle Scholar
- Shojaei F, Ferrara N: Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat. 2008, 11: 219-230. 10.1016/j.drup.2008.09.001.View ArticlePubMedGoogle Scholar
- Schrag D: The price tag on progress–chemotherapy for colorectal cancer. New Eng J Med. 2004, 351: 317-319. 10.1056/NEJMp048143.View ArticlePubMedGoogle Scholar
- Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006, 42: 3127-3139. 10.1016/j.ejca.2006.09.015.View ArticlePubMedGoogle Scholar
- Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007, 7: 475-485. 10.1038/nrc2152.View ArticlePubMedGoogle Scholar
- Le Tourneau C, Siu LL: Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opinion Oncol. 2008, 20: 256-263. 10.1097/CCO.0b013e3282f9b575.View ArticleGoogle Scholar
- Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY: Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001, 82: 49-56. 10.1006/gyno.2001.6235.View ArticlePubMedGoogle Scholar
- Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Brit J Cancer. 2009, 101: 967-972. 10.1038/sj.bjc.6605212.View ArticlePubMedPubMed CentralGoogle Scholar
- Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F: Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol. 1993, 13: 276-288.View ArticlePubMedPubMed CentralGoogle Scholar
- Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003, 22: 1517-1527. 10.1038/sj.onc.1206226.View ArticlePubMedGoogle Scholar
- Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Lingen M, Strieter RM, Nunez G, Nör JE: Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007, 67: 9685-9693. 10.1158/0008-5472.CAN-07-1497.View ArticlePubMedGoogle Scholar
- Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE: Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009, 11: 583-593.View ArticlePubMedPubMed CentralGoogle Scholar
- Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, Polverini PJ: Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest. 2001, 81: 453-463. 10.1038/labinvest.3780253.View ArticlePubMedGoogle Scholar
- Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ: Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001, 61: 2183-2188.PubMedGoogle Scholar
- Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nor JE: Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia. 2008, 10: 131-139. 10.1593/neo.07815.View ArticlePubMedPubMed CentralGoogle Scholar
- Squarize CH, Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS: Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia. 2006, 8: 733-746. 10.1593/neo.06274.View ArticlePubMedPubMed CentralGoogle Scholar
- Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007, 117: 3846-3856. 10.1172/JCI31871.View ArticlePubMedPubMed CentralGoogle Scholar
- Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007, 117: 3988-4002. 10.1172/JCI32533.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007, 130: 691-703. 10.1016/j.cell.2007.06.054.View ArticlePubMedPubMed CentralGoogle Scholar
- Fletcher S, Turkson J, Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 2008, 3: 1159-1168. 10.1002/cmdc.200800123.View ArticlePubMedPubMed CentralGoogle Scholar
- Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H: Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2006, 1091: 151-169. 10.1196/annals.1378.063.View ArticlePubMedGoogle Scholar
- Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007, 26: 3291-3310. 10.1038/sj.onc.1210422.View ArticlePubMedGoogle Scholar
- Friday BB, Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008, 14: 342-346. 10.1158/1078-0432.CCR-07-4790.View ArticlePubMedGoogle Scholar
- Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003, 4: 257-262. 10.1016/S1535-6108(03)00248-4.View ArticlePubMedGoogle Scholar
- Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev Cancer. 2002, 2: 489-501. 10.1038/nrc839.View ArticleGoogle Scholar
- Grant S: Cotargeting survival signaling pathways in cancer. J Clin Invest. 2008, 118: 3003-3006.View ArticlePubMedPubMed CentralGoogle Scholar
- Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008, 118: 3051-3064.PubMedPubMed CentralGoogle Scholar
- Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008, 118: 3065-3074.PubMedPubMed CentralGoogle Scholar
- Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C: Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2006, 103: 14477-14482. 10.1073/pnas.0606836103.View ArticlePubMedPubMed CentralGoogle Scholar
- McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM: Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzym Regul. 2007, 47: 64-103. 10.1016/j.advenzreg.2006.12.013.View ArticleGoogle Scholar
- Kamran MZ, Patil P, Gude RP: Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013, 2013: 421821-View ArticlePubMedPubMed CentralGoogle Scholar
- Piperi C, Samaras V, Levidou G, Kavantzas N, Boviatsis E, Petraki K, Grivas A, Barbatis C, Varsos V, Patsouris E, Korkolopoulou P: Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine. 2011, 55: 387-395. 10.1016/j.cyto.2011.05.012.View ArticlePubMedGoogle Scholar
- Monk BJ, Willmott LJ, Sumner DA: Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol. 2010, 116: 181-186. 10.1016/j.ygyno.2009.09.033.View ArticlePubMedGoogle Scholar
- Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer. 2008, 8: 592-603. 10.1038/nrc2442.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/99/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.